Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410343 | 1.00 | CTSK (0.42) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL12676608 | 1.00 | CTSK (0.42) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL12410348 | 0.96 | CTSK (0.41) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL12629250 | 0.95 | CTSK (0.40) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL12629360 | 0.95 | CTSK (0.40) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL4294234 | 0.95 | CTSK (0.40) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL13623345 | 0.95 | CTSK (0.40) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL13043784 | 0.90 | CTSK (0.43) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL15025942 | 0.90 | CTSK (0.43) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL12762362 | 0.90 | CTSK (0.43) | CTSKCTSSCTSLCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308282-B2 | [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9308282-B2 | [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | LIFE MOLECULAR IMAGING SA (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | LIFE MOLECULAR IMAGING SA (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| EP-2282982-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID- AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141091-A1 | NOVEL [F-18] -LABELLED L-GLUTAMIC ACID- AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| EP-2123621-A1 | New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (1), application thereof and method for their manufacture | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | CTSK 2573/4885CTSS 2938/4885CTSL 2321/4885 |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | CTSK 2573/4885CTSS 2938/4885CTSL 2321/4885 |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | CTSK 2187/4885CTSS 2870/4885CTSL 2240/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | CTSK 2281/4885CTSS 3084/4885CTSL 2391/4885 |
| US-20110165076-A1 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION | GLUL, QPCT, GFPT1 | CTSK 2837/4885CTSS 3600/4885CTSL 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.